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The end-stage renal disease (ESRD) population requiring
chronic maintenance dialysis or renal transplantation is growing at
an exponential rate, with over 62,000 incident (newly developed
ESRD) cases reported per year in the United States [1]. This
patient population experiences an excess morbidity and mortality
due to arteriosclerotic cardiovascular disease (CVD) outcomes
[1—5]. Specifically, event rates for myocardial infarction and stroke
are 5- to 10-fold higher in ESRD versus general populations [1—5].
Traditional CVD risk factors, such as smoking, hypertension,
glucose intolerance/diabetes, and dyslipidemia [6], despite their
widespread prevalence [7], are relatively limited predictors of
CVD-specific morbidity and mortality in the ESRD population
[7—111. Wu [10], for example, reported that the two-year cumula-
tive incidence of de novo coronary heart disease (CHD) in ESRD
patients undergoing chronic peritoneal (18.0%) or hemodialysis
(15.0%), exceeded the six-year cumulative incidence (12.7%) of
de novo CHD among original Framingham Study cohort partici-
pants similarly free of baseline CHD, and frequency matched to
the dialysis patients for prevalence of the established CVD risk
factors.
Recently, controlled evidence [12] has been provided that
hyperhomocysteinemia, that is, elevated total plasma levels of the
atherothrombotic sulfur amino acid homocysteine [13, 14], occurs
more commonly than any of the traditional CVD risk factors in
ESRD patients on maintenance dialysis. Initial follow-up data
further suggest that the markedly elevated fasting plasma total
homocysteine (tHcy) levels found in these dialysis-dependent
ESRD patients contributes independently to their excess inci-
dence of fatal and non-fatal CVD outcomes [15]. Confirmation of
these prospective findings in more sizable ESRD cohorts is
urgently required.
This review will first place hyperhomocysteinemia in the context
of the other established amino acid abnormalities characteristic of
ESRD. What is known from studies of general and ESRD
populations about the prevalence and pathogenesis of hyperho-
mocysteinemia will then be summarized, followed by discussions
of the epidcmiological and experimental evidence linking hyper-
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homocysteinemia to arteriosclerotic outcomes, and an overview of
Hey-lowering therapeutic interventions.
AMINO ACID ABNORMALITIES IN ESRD
Detailed, elegant studies of amino acid metabolism (that is,
relying upon direct, in vivo measurement of arteriovenous amino
acid concentration differences across the kidneys, along with
simultaneous determination of renal plasma flow, urine flow, and
urinary amino acid concentration) have been reported by Brosnan
[16] and Tizianello and colleagues [17]. These data have high-
lighted the major "unexpected" [16] role normally played by the
kidneys in amino acid metabolism. As a consequence, significant,
predictable changes in plasma amino acid levels accompany
chronic renal insufficieney/ESRD-induced alterations of norma-
tive renal amino acid metabolism. For example, measurement of
arteriovenous differences for free amino acids across normative
kidneys reveals that glycine and citrulline are removed, and serine
and arginine added to the circulation [16, 17]. Under conditions
requiring the excretion of substantial quantities of acid (such as
diabetes, high intakes of dietary protein), large amounts of
glutamine, the major precursor of urinary ammonia, are taken up
[16]. Not surprisingly, the uptake of glycine and citrulline, and the
release of serine and arginine are all reduced in chronic renal
insufficiency [17]. Furthermore, serine and arginine levels are
lower, while the levels of glycine and citrulline tend to be higher,
in patients with chronic renal insufficiency or ESRD [18, 19].
Recently, in collaboration with Dr. Brosnan's group, we provided
the first in vivo demonstration that there is consistent, significant
net renal uptake and metabolism of Hey among post-absorptive
state rats [20]. How these findings may be relevant to the
B-vitamin refractory hyperhomocysteinemia frequently observed
in ESRD will be elaborated in a subsequent section.
DETERMINANTS OF PLASMA/SERUM HOMOCYSTEINE
LEVELS, AND THE PREVALENCE AND ETIOLOGY OF
HYPERHOMOCYSTEINEMIA
General populations
Homocysteine is a non-protein forming, sulfur amino acid
whose metabolism is at the junction of two metabolic pathways
[21]: remethylation and transsulfuration (Fig. 1). In remethyla-
tion, homocysteine acquires a methyl group from N-5-methyltet-
rahydrofolate (MTHF) or from betaine to form methionine. The
reaction with MTHF occurs in all tissues and is vitamin B12-
dependent, while the reaction with betaine is confined mainly to
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Fig. 1. Homocysteine metabolism. Enzyme reactions that are regulated by S-adenosylmethionine (SAM) and 5-methyltetrahydrofolate (Methy-THF)
are indicated by large arrows. Open arrows indicate activation, closed arrows indicate inhibition. Enzymes: (1) 5,10 methylenetetrahydrofolate
reductase; (2) methionine synthase; (3) S-adenosylmethionine synthase; (4) S-adenosylhomocysteine hydrolase; (5) cystathionine beta synthase; (6)
betaine:homocysteine methyltransferase; (7) glycine N-s; (8) serine hydroxymethylase; (9) cystathionase. (Reprinted with permission from: Folic acid
(chapt 21), in Present Knowledge in Nutrition, edited by SELHUB J, ROSENBURO IH, International Life Sciences Institute, 1996, p 209).
the liver (and kidneys, in humans [22]), and is vitamin B12-
independent. A considerable proportion of methionine is then
activated by ATP tO form S-adenosylmethionine (SAM). SAM
serves primarily as a universal methyl donor to a variety of
acceptors including guanidinoacetate (for creatine-creatinine syn-
thesis), nucleic acids, neurotransmitters, phospholipids, and hor-
mones. S-adenosylhomocysteine (SAH), the byproduct of these
methylation reactions, is subsequently hydrolyzed, thus regener-
ating homocysteine, which then becomes available to start a new
cycle of methyl-group transfer.
In the transsulfuration pathway, homocysteine condenses with
serine to form cystathionine in an irreversible reaction catalyzed
by the pyridoxal-5 '-phosphate (PLP)-containing enzyme, cystathi-
onine beta synthase (CBS). Cystathionine is hydrolyzed by a
second PLP-containing enzyme, cystathionase, to form cysteine
and alpha-ketobutyrate. Excess cysteine is oxidized to taurine and
inorganic sulfates or excreted in the urine. Thus, in addition to the
synthesis of cysteine, the transsulfuration pathway effectively
catabolizes excess homocysteine which is not required for methyl
transfer. Homocysteine is not a normal dietary constituent, so the
sole source of homocysteine is methionine. Finally, it is important
to understand that valid, modern assays of routinely handled fresh
blood samples, and all short- or long-term frozen specimens,
measure total homocysteine in plasma or serum [23]. Approxi-
mately 70 to 80% of circulating plasma/serum total homocysteine
(tHey) is bound to large proteins (such as albumin [23]), the
remainder consisting of a "free" acid-soluble fraction, that is,
reduced Hcy (< 1%), homocystine disulfide, and the predominant
non protein-bound forms, Hey-mixed disulfides [23].
Due to the existence of a cellular homocysteine export mecha-
nism, plasma normally contains a small amount of homocysteine
averaging 10 rmol/liter [23]. This export mechanism complements
the catabolism of homocysteine through transsulfuration; to-
gether these mechanisms help maintain low intracellular concen-
trations of this potentially cytotoxic sulfur amino acid. In hyper-
homocysteinemia, plasma homocysteine levels are elevated and,
barring renal insufficiency, the occurrence of hyperhomocysteine-
mia indicates that homocysteine metabolism has in some way
been disrupted, causing the export mechanism to dispose into the
blood excess homocysteine that has accumulated in the cell. This
limits intracellular toxicity, but leaves vascular tissue exposed to
the possibly deleterious effects of excess homocysteine.
The more severe cases of hyperhomocysteinemia are due to
homozygous defects in genes encoding for enzymes of homocys-
teine metabolism. In such cases, a defective enzyme involved in
either homocysteine remethylation or transsulfuration leads to
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large elevations of homocysteine in the blood and urine. The
classic form of such a disorder is that caused by homozygosity for
a defective gene encoding for cystathionine beta synthase (CBS),
a condition in which fasting plasma homocysteine concentrations
can be as high as 400 j.mol/liter [24]. Homozygous defects of
other genes that lead to similar elevations in plasma homocysteine
concentration include those encoding for methylenetetrahydrofo-
late reductase (MTHFR) [25] or for any of the enzymes that
participate in the synthesis of methylated vitamin B12 [26].
Recently the cDNA has been isolated, and point mutations
described, for the vitamin B12-dependent enzyme methionine
synthase (Dr. R. Rozen, personal communication). However, the
functional impact on enzyme activity and/or the clinical relevance
of these mutations has not been elucidated.
Most cases of hyperhomocysteinemia are moderate in charac-
ter, and may be due to defects in genes encoding for Hey-
metabolizing enzymes or from deficiencies in vitamins that are
involved in Hcy metabolism. Plasma Hcy concentrations in these
instances may differ depending on which arm of the two metabolic
pathways of homocysteine metabolism is defective. (For full
details see [21])
(1.) An impairment in the remethylation pathway, even if it is
mild, will lead to a substantial increase in plasma homocysteine
concentrations under fasting conditions. Such an impairment may
be due to defects in the gene encoding for MTHFR or deficiencies
of either folate or vitamin B12 [21].
(2.) In contrast, a mild impairment in the transsulfuration
pathway will lead, at most, to a very slight increase in fasting
plasma homocysteine levels. This mild impairment, which may be
due to heterozygous defects in the CBS gene or deficiency in
vitamin B6 [21], is normally identified by the methionine loading
test [21]. As Brattstrom, Israelsson and Hultberg first noted [27],
however, it is critical to define the post-methionine loading (PML)
response based on the increase in tHcy above fasting levels, to
avoid confounding by fasting hyperhomocysteinemia.
Studies conducted in vitamin deficient animal models support
this hypothesis. Miller and colleagues have shown that fasting
plasma homocysteine concentrations are 10-fold higher in folate
deficient rats than in folate supplemented rats, and that these high
concentrations of tHcy in plasma are in part due to lack of
sufficient 5-adenosylmethionine for the activation of the transsul-
furation pathway [28]. A second study demonstrated that after
methionine loading, the tHcy concentrations increased 35-fold in
rats that were vitamin B6 deficient compared to about fourfold in
control rats and less than 35% in folate deficient rats [29].
Preliminary data from 274 participants in the Family Heart Study
provide human evidence to further support the hypothesis of two
distinct forms of hyperhomocysteinemia [30]. For each partici-
pant, plasma tHcy concentrations were determined under fasting
conditions, and four hours after a methionine load. Using the 90%
percentile values to define hyperhomocysteinemic (both fasting
and 4-hour PML), it was demonstrated that out of 43 hyperho-
mocysteinemia individuals, 20 (46%) had fasting hyperhomocys-
teinemia only, 17 (39.5%) had PML hyperhomocysteinemia only
and only 7 (14%) had both fasting and PML hyperhomocysteine-
mia. Following validation of an abbreviated (that is, 2 hour)
protocol [31] these analyses were replicated in 294 individuals who
underwent two-hour PML tests, and the results obtained were
identical (Dr. A. Bostom, unpublished data).
Both genetic disorders and nutritional status may influence the
prevalence of hyperhomocysteinemia, but there are few data to
indicate how important these determinants might be in the
general population. The independent associations between indi-
vidual nutrients and non-fasting tHey concentrations in an estab-
lished cohort of Americans (the Framingham Study cohort) were
first examined by Selhub and colleagues [32]. Approximately
two-thirds of all cases of elevated homocysteine levels (based on
non-fasting samples) were associated with inadequate status of
one or more of the nutritional co-factors/substrates involved in
Hey metabolism, suggesting that the most important cause of
hyperhomocysteinemia, from a public health standpoint, may be
inadequate nutritional status. More recently, it was shown that
nutritional status modifies the relationship between a genetic
variant of an enzyme involved in the remethylation pathway of
Hey metabolism, and fasting tHey levels [33]. This common
variant of methylenetetrahydrofolate reductase (MTHFR), which
has a lower specific activity and greater sensitivity to heat inacti-
vation (hence the name thermolabile MTHFR), is the result of a
C to T transition at nucleotide 677 of the MTHFR gene [34, 35].
The C677T transition results in an alanine (ala) to valine (val)
substitution in the expressed enzyme, and has an allele frequency
of about 35%, and homozygote frequency of about 12% [33, 35].
A study of 365 participants in the NHLBI Family Heart Study
revealed that homozygotes (val-val) for the ala to val substitution
had higher geometric mean fasting plasma tHey levels than
(ala-val) heterozygotes or homozygotes (ala-ala) for the normal
enzyme when folate status was below the median (< 6.8 ng/ml),
but no differences were detected between individuals with differ-
ent genotypes when folate status was at the median or above
( 6.8 ng/ml). In accord with the hypothesis that remethylation
defects have no significant independent effect on PML tHey
levels, there was no difference in the geometric mean PML
increase in tHey levels among the different MTHFR genotype
groups [33].
Creatinine [36—38] and albumin [39] are two additional, inde-
pendent determinants of tHey levels in general populations,
unrelated to B-vitamin status. The generation of s-adenosylhomo-
cysteine from s-adenosylmethionine is coupled to creatine-creat-
mine synthesis [40], which likely accounts for the direct associa-
tion observed between creatinine and fasting tHey levels in
persons with normative renal function [36—39]. As noted earlier,
70 to 80% of serum/plasma tHey is protein-bound, most likely to
albumin [23], which may account for the direct relationship
observed between albumin and tHey levels in the general popu-
lations [39]. Finally, acute reductions in plasma tHey documented
in patients hospitalized for cerebral infarctions are believed to be
linked to parallel decreases in albumin [41].
ESRD populations
Seventeen independent investigations [42—58] published be-
tween 1972 and 1996 have documented markedly increased
plasma or serum levels of free, protein-bound, or tHey among
ESRD patients in the pre-dialysis phase, while undergoing main-
tenance dialysis, and following renal transplantation. Reports by
our group were the first studies documenting the prevalence of
hyperhomocysteinemia in dialysis-dependent ESRD patients rel-
ative to age, sex, and race matched, population-based controls
free of clinical renal disease, whose serum creatinine levels were
1.5 mg/dl or less [12, 541. These data (also, Fig. 2 and Table 1)
indicated that hyperhomocysteinemia (fasting tHey levels > 13.9
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Fig. 2. Distributions of fasting tHcy levels in (N = 71) dialysis.dependent
ESRD patients, and (N = 71) age, sex, and race matched Framingham
Ofispring/Omni Study controls free of renal disease, with serum creati-
nine levels 1.5 mgldl. Data are from Bostom et al [121. Symbols are: ()
control; (•) ESRD.
j.tmol/liter, the 90th percentile control value) occurred in 83% of
the dialysis patients, a 105-fold increased risk (matched preva-
lence odds) relative to the controls. Three basic questions arise
from these findings:
(1.) Are the major established determinants of tHcy levels in
general populations equally important in ESRD populations?
(2.) Are there significant determinants of tHcy levels specific to
the ESRD population, related, for example, to the etiology and
treatment of ESRD?
(3.) Are there unique pertubations of normal tHcy metabolism
in ESRD that account for the excess prevalence of hyperhomo-
cysteinemia observed in this patient population?
Dialysate losses of water-soluble vitamins, including the B-
vitamins, and restricted overall dietary intake patterns, are the
rationale for the clinical practice of providing routine multivita-
mm supplementation to dialysis-dependent ESRD patients [59].
Additional evidence suggests that uremia may result in increased
hydrolysis of plasma PLP, reducing the supply of this coenzyme to
peripheral tissues [60, 61]. In the clinical setting, therefore,
investigators are confronted with a population who, although at
heightened risk for deficiencies in Hey-metabolizing coenzymes/
substrates, is most often receiving routine supplementation with
greater than RDA (recommended daily allowance) amounts of
these micronutrients (that is, folic acid, B-6, and B-12). Awareness
of these opposing influences on plasma B-vitamin status is impor-
tant when evaluating studies of homocysteinemia in clinical
ESRD populations.
Wilcken and Gupta [44] made the initial observation that
cysteine-homocysteine mixed disulfide (MDS) levels were directly
correlated with serum creatinine levels in N = 22 patients with
mild to severe renal impairment (that is, serum creatinine 130 to
Table 1. Total homocysteine (tHcy) and B-vitamin levels in
maintenance dialysis patients, renal transplant recipients, and their
respective, matched population-based control groups
MDP RTR
MDP controls P RTR controls P
(N = 71) (N = 71) value" (N = 29) (N = 58) valu&'
tHcy pinol/liter
-fasting 21.7" 9.6 <0.001 18.1 9.8 <0.001
-PM!]' — — — 22.0 15.2 0.001
Folate ng/ml 21.3 7.6 <0.001 3.2 7.0 0.019
PLPpmoi/ml 59.0 65.9 0.474 40.3 54.4 0.073
B-12 pg/mi 632.5 421.4 <0.001 426.0 367.3 0.072
Abbreviations are: MDP, maintenance dialysis patients; RTR, renal
transplant recipients.
a Based on paired t-test of geometric means, MDP vs. age, sex, and race
matched (1:1) controls free of renal disease
hBased on conditional analysis of variance comparisons of geometric
means, RTR vs. age and sex matched (2:1) controls free of renal disease
Geometric means
d Post-methionine load increase in tHey above fasting levels (from
Bostom et al [12].
1160 ,itmol/liter). Circulating levels of folate, PLP, or B-12 were
not determined, but the authors noted that all patients were
receiving supplements containing these vitamins, and they con-
cluded it was "unlikely" that the observed increase in cysteine-
homocysteine MDS was related to "shortages of these cofactors."
In a related study of 27 stable renal transplant recipients, Wilcken
and colleagues [46] reported similar findings regarding the asso-
ciation between creatinine and cysteine-homocysteine MDS
within a relatively narrower range of serum creatinine, consistent
with less impaired renal function (that is, serum creatinine of
—100 to 500 mol/liter). Short-term (4-weeks) folic acid-based
B-vitamin supplementation, given as part of an uncontrolled,
open-label subgroup study of 11 arbitrarily-selected renal trans-
plant recipients, reduced fasting cysteine-homocysteine MDS
levels by 41%. Wilcken, Gupta and Betts [46] concluded that
"relative shortages of folic acid" might have contributed to the
"moderately elevated" cysteine-homocysteine MDS levels they
observed in these patients. Hultberg, Andersson and Sterner [50]
assessed the crude correlations between fasting tHcy and serum
B-12, red blood cell folate, serum creatinine, and other routine
biochemical parameters in ESRD patients in the pre-dialysis
phase (N = 30), on maintenance peritoneal dialysis (N = 17), and
maintenance hemodialysis (N = 29). They reported the following
significant crude rank-order (Spearman's rho) correlations: serum
creatinine in the pre-dialysis stage ESRD patients (r = +0.70, P <
0.001), and CAPD patients (r = +0.49, P < 0.05); red blood cell
folate in the pre-dialysis stage ESRD patients (r =
—0.43, P <
0.05), and CAPD patients (r = —0.59, P < 0.05); serum albumin
in the predialysis stage ESRD patients (r = +0.39, P < 0.05) and
hemodialysis patients (r = +0.39, P < 0.05); and serum B-12 in
the CAPD patients only (r = —0.49, P < 0.05). Using general
linear modeling with analysis of covariance, we [62] performed a
comprehensive assessment of the potential determinants of fast-
ing plasma tHey levels in 75 maintenance dialysis patients (N = 50
on hemodialysis; N = 25 on CAPD). Approximately 95% of these
patients were prescribed ito 2 mg of folic acid, 10 mg of B-6, and
12 ig of B-12 daily. Fasting tHey, folate, PLP, B-12, creatinine,
glucose, and total and HDL-cholesterol levels were determined,
along with measures of dialysis adequacy/residual renal function.
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Etiology of ESRD, presence of clinical cardiovascular disease
(CVD), the traditional CVD risk factors (such as, smoking,
hypertension, diabetes/glucose intolerance, dyslipidemia, age, and
sex), the C677T transition in the MTHFR gene, and length of
time since first initiation of dialysis, were also ascertained. Con-
sistent with findings from the investigation of Hultberg and
colleagues [501, we observed unadjusted correlations between
fasting plasma tHcy and plasma folate, B-12, and serum creati-
nine. We also reported the first crude correlation between plasma
PLP status, and fasting tHcy levels in this patient population.
Multivariable-adjusted analyses, however, revealed that plasma
folate status (into the supernormal range) and serum creatinine
were the only significant, independent predictors of fasting tHcy
levels. Subsequent analyses in which albumin levels were added to
these models confirmed that serum albumin was also an indepen-
dent determinant of fasting tHey levels (Dr. A. Bostom, unpub-
lished data). Presence of the C677T transition in MTHFR (that is,
pooled CT heterozygotes and TF homozygotes, vs. CC wild types)
appeared to interact with folate status to increase fasting tHcy
levels only in those patients with folate levels below the median
[62]. Larger, preliminary analyses including MTHFR genotype
data from twice as many subjects (N = 140 vs. N = 68) suggest
that the "true" interaction may be occurring only in MTHFR rr
homozygotes who have folate levels below the general population
median (< 6.8 nglml) as opposed to below the dialysis population
median (< 20 to 30 ng/ml; Dr. A. Bostom, unpublished data). We
also provided the initial data regarding potential determinants of
homocysteinemia unique to the dialysis-dependent ESRD popu-
lation, such as the cause of ESRD, and the effect of treatment
modality or adequacy [62]. There was no evidence that either the
etiology of ESRD, the length of time since first initiation of
dialysis, dialysis mode (that is, standard 3 times weekly hemodi-
alysis vs. CAPD), or measures of dialysis adequacy (urea reduc-
tion ratios) or residual renal function (weekly creatinine clear-
ance), have any significant, independent effect on chronic tHcy
levels in maintenance dialysis patients [621. Finally, although
hemodialysis results in a transient reduction of plasma tHcy of
—30% [50, 63, 64], consistent with removal of the nonprotein-
bound, dialyzable fraction of Hey, there is a rapid return to
predialysis tHey levels within 24 hours [50].
Limited data are available on the prevalence and determinants
of hyperhomocysteinemia in stable renal transplant recipients [46,
53, 57]. We recently provided more adequately controlled confir-
mation of these earlier reports [46, 53, 57] describing an increased
prevalence of fasting hyperhomocysteinemia in renal transplant
recipients (Table 1; Note added in proof, A). In addition, our study
provided the first documentation of an apparent excess preva-
lence of PML hyperhomocysteinemia (matched odds ratio 6.9),
and combined fasting and PML hyperhomocysteinemia (matched
odds ratio 18.0) in renal transplant recipients versus age and
sex-matched population-based controls with normative renal
function. These data also suggested that suboptimal folate and
B-6 status are common in renal transplant recipients (who, unlike
maintenance dialysis patients, are not routinely supplemented
with these vitamins), confirming two reports from the early I 980s
[65, 66]. Furthermore, our findings indicated that residual renal
function may be a particularly crucial determinant of homocys-
teinemia in renal transplant recipients, both under fasting condi-
tions, and PML.
Wilcken and Gupta [44] originally suggested that the etiology of
hyperhomocysteinemia in ESRD might be due to loss of urinary
Hey excretion, or the adverse effect of uremia on Hey-metaboliz-
ing enzymes. Noting that normal kidneys release approximately
4 g of serine per day into the circulation [16], and ESRD patients
have significantly depressed plasma serine levels [18, 19], we
hypothesized that relative serine depletion might compromise the
initial step of Hey transsulfuration, that is, the condensation
between Hey and serine catalyzed by CBS [54]. As described
below, however, none of these hypotheses have been substanti-
ated in relevant animal model, or human studies.
Stabler and colleagues [671 were the first to demonstrate that
urinary excretion of Hey in healthy humans is trivial, an observa-
tion confirmed in subsequent studies of both humans [68, 69] and
rats [201. Furthermore, Hultberg and colleagues [50] reported that
ESRD patients (who were not anuric) exhibited a greater urinary
Hey clearance in comparison to normal renal function controls.
They reasoned that a decline in the normally avid (as earlier
demonstrated by Foreman and colleagues in vitro [70]) tubular
reabsorption of Hey, more than offset any decrease in urinary Hey
excretion in these patients due to a reduction in their glomerular
filtration rate. Thus, despite greater urinary Hey clearance [54],
ESRD patients maintain a chronic two- to threefold increase in
plasma tHey levels, relative to persons with normative renal
function [12; 49—58]. Bocock and Zlotkin [71] found that hepatic
CBS activity was normal in uremic rats. In addition, Guttormsen
and colleagues [72] reported normative increases in plasma
methionine following peroral L-homoeysteine loading in subjects
with ESRD who were folate and B-12 replete. These combined
observations [71, 72] do not support the hypothesis that ESRD
has an adverse effect on extrarenal transsulfuration or remethy-
lation of Hey. Finally, we conducted an investigation that failed to
confirm our hypothesis regarding the potential role of depressed
serine levels in the etiology of ESRD hyperhomocysteinemia.
Supplementation with 3 to 4 g of L-serine per day raised plasma
serine levels by almost 40%, but had no effect on fasting tHey
levels in four hyperhomocysteinemic hemodialysis patients whose
baseline serine levels were below the 10th percentile distribution
of a matched healthy control population free of renal disease [541.
In stark contrast to the aforementioned hypotheses, clear and
consistent evidence has been provided supporting the notion that
loss of normal renal metabolism plays a crucial role in the
B-vitamin refractory [12] hyperhomocysteinemia frequently ob-
served in ESRD. We determined net renal uptake and metabo-
lism of tHey using an established rat model for measuring
arteriovenous amino acid differences across the rat kidney, along
with simultaneous measurement of renal plasma flow, urine flow,
and urinary tHey levels [20]. Uniformly higher renal artery versus
renal vein plasma tHey levels were observed. The resulting
(positive) renal arteriovenous difference for tHey was equivalent
to 20% (0.92/4.53 nmol/ml) of the mean arterial plasma tHey
level. Calculated mean renal tHey uptake and metabolism (8.07
5.31 nmol/min) was markedly greater (P = 0.024) than mean
urinary tHey excretion (0.19 0.10 nmol/min). These data
provided the first in vivo confirmation of significant Hey metabo-
lism, along with minimal urinary excretion, by the normative rat
kidney. When extrapolated to humans, we calculated that an
equivalent arteriovenous difference for tHey across the human
kidney, at a renal plasma flow of 650 mI/mm, subtracting the trivial
urinary tHey excretion, would yield a tHey uptake and metabolism
by normative kidneys of approximately 1 mmol/day. Although
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Unadjusted
Adjusted for folate
Adjusted for folate, PLP,
B-12, albumin, age,
sex, smoking, and
CVD
Abbreviations are: MDP, maintenance dialysis patients; RTR, renal
transplant recipients; CVD, cardiovascular disease.
a Derived from between group comparisons of geometric means by
unpaired t-test (unadjusted), or general linear modeling with analysis of
covariance (folate, and multivariable-adjusted)
(from Bostom et at [62], and Note added in proof, B)
daily Hey production is an estimated 15 to 20 mmol/day in humans
[401, most of this Hey is metabolized intracellularly [23], and
approximately 1.5 mmol/day or less is normally exported into the
plasma compartment [69]. Thus, our calculations suggested that
renal uptake and metabolism could account for —70% (1 mmol/
day 184 1.5 mmol/day) of daily tHey elimination from plasma.
Remarkably concordant findings from a study examining plasma
tHey elimination in healthy human subjects, and those with
ESRD, were recently presented by Guttormsen and colleagues
[72]. Plasma tHey responses to oral L-homocysteine loading were
compared in the ESRD patients and healthy controls. The
elimination rate of tHey from plasma was decreased (that is, the
elimination half-life was increased), and the systemic exposure
(area under the curve) was markedly greater in the ESRD
patients versus the matched, normative renal function controls.
Pharmacokinetic modeling revealed an increase in the half-life of
elimination from a mean of 3.5 hours in the controls, to 11.0 hours
in the ESRD patients. These data are consistent with a 70%
reduction in plasma tHey clearance due to ESRD. Despite in vitro
evidence of both specific and nonspecific renal tubular transport
mechanisms for Hey [701, and the documented presence of the
major remethylation (methionine synthase, betaine:homocysteine
methyltransferase) and transsulfuration (CBS) enzymes in human
kidney [22; 73—751, the fate of intrarenal Hey remains unknown.
Hopefully, elucidating the specific details of renal Hey metabolism
will receive increased attention in the future. In the interim,
additional observations from studies of ESRD patients confirm
that the kidneys play a pivotal role in tHey elimination from
plasma. For example, preliminary data suggest that successful
renal transplantation subacutely reduces fasting tHey levels by
approximately 33% [76]. In a complementary study (Note added
in proof, B) we recently demonstrated that partial restoration of
renal function following successful renal transplantation results in
a chronic reduction in fasting tHey levels relative to ongoing
maintenance dialysis treatment of ESRD patients (Table 2).
Geometric mean fasting tHey levels, adjusted for age, sex, plasma
folate, PLP, and B-12, serum albumin, and the presence of
cardiovascular disease, were 23.4% lower in N = 29 stable renal
transplant recipients, in comparison to N = 73 maintenance
dialysis patients (17.0 .Lmol/liter vs. 22.2 tmol/liter, P = 0.008).
Moreover, delayed tHey elimination after methionine loading has
been demonstrated in subjects with ESRD [63], which likely
First incident
non-fatal or Fatal CVD
fatal CVD Only (9
(16 Events) Events)
Hazards ratio (95% Cl)
Unadjusted 3.6 (1.3—9.6) 7.1 (1.8—28.4)
Adjusted for:
Age 3.5 (1.3—9.5) 6.7 (1.6—26.8)
Sex 3.9 (1.4—10.4) 7.2 (1.8—29.3)
Age and sex 3.9 (1.4—10.5) 7.1 (1.7—29.2)
Race 3.7 (1.4—9.8) 7.1 (1.8—28.5)
Total cholesterol 3.1 (1.1—8.7) 6.4 (1.6—26.5)
Total/HDL cholesterol 3.5 (1.3—9.3) 7.t) (1.7—27.9)
Total/HDL cholesterol > 6 3.6 (1.3—9.6) 7.1 (1.8—28.3)
Glucose intolerance 4.2 (1.6—11.5) 7.6 (1.9—30.6)
Diabetes 4.4 (1.6—12.0) 7.4 (1.9—29.9)
Hypertension 3.8 (1.4—10.3) 7.9 (1.9—32.2)
Smoking 3.0 (1.1—8.1) 7.1 (1.7—29.6)
Baseline CVD 4.4 (1.6—12.2) 10.3 (2.4—43.2)
Albumin 3.5 (1.3—9.4) 7.7 (1.9—31.9)
Creatinine 3.7 (1.4—10.0) 8.1 (2.0—32.6)
Dialysis mode 3.6 (1.3—9.5) 8.1 (2.0—32.6)
Months since dialysis initiation 3.6 (1.3—9.6) 7.3 (1.8—29.5)
Low residual adequacy or 3.5 (1.3—9.6) 6.5 (1.6—26.8)
residual renal function
contributes to the mild PML hyperhomocysteinemia observed in
both maintenance dialysis patients [50, 631 and stable renal
transplant recipients (Dr. A. Bostom, unpublished data). An
elegant study by Arnadottir and colleagues [77] examined the
association between a direct measure (that is, iohexol clearance)
of glomerular filtration rate (GFR), and fasting plasma tHey
levels in a select group of patients (N = 64) with renal function
ranging from normal to predialysis ESRD. Plasma tHey levels
were strongly correlated (Spearman's rho =
—0.70, P < 0.001)
with GFR. Significantly increased tHey levels (+34%, P < 0.01)
were already apparent in the group with moderately reduced GFR
[mean (± standard deviation) 51 10 ml min1, adjusted for
body surface area]. A strong crude correlation (r = +0.69, P <
0.01) between creatinine and fasting tHey levels was also ob-
served. Multivariable regression analysis, however, revealed that
only GFR and red blood cell folate remained independent
predictors of tHey levels in models including creatinine and other
potential determinants, such as PLP and B-12 levels. Finally,
within the very narrow range characteristic of dialysis-dependent
ESRD, we found no correlation between residual renal function
(as determined by weekly creatinine clearance in CAPD patients),
and fasting tHey levels [621. This observation may explain, in part,
why increased age, a surrogate for declining glomerular filtration
rate [78], and a significant determinant of tHey levels in general
populations [36—39], was not associated with fasting tHey levels in
the dialysis patients.
HOMOCYSTEINE AND ARTERIOSCLEROSIS:
EPIDEMIOLOGICAL EVIDENCE
General population data
In 1969, the seminal observations of McCully first linked
marked hyperhomocysteinemia to precocious arteriosclerotic dis-
ease in autopsied children who died from distinct metabolic forms
Table 2. Comparison of crude and adjusted geometric mean fasting
total homocysteine levels (j.tmol/liter) in maintenance dialysis patients
and stable renal transplant recipients
MDP RTR % P
(N = 73) (N = 29) Difference value
21.6 18.1 16.2%
22.5 16.4 27.1%
22.2 17.0 23.4%
Table 3. Relative risk estimates (hazards ratios) for incident CVD
associated with plasma tHey levels 27 jmol/liter in dialysis-dependent
ESRD patients [15]
0.07
<0.001
0.008
16 Bostom and Lathrop: Hyperhomocysteinemia in ESRD
of homocystinuria [13]. Nearly thirty years later, a burgeoning
amount of observational evidence has accumulated indicating that
mild to moderate fasting or non-fasting hyperhomocysteinemia
(tHey levels 14 j.mol/liter to 100 j.tmol/liter [23]) is an
independent risk factor for arteriosclerotic outcomes. The recent
meta-analysis of Boushey and colleagues [79], primarily represent-
ing findings from retrospective studies, suggested each 5 iimol/
liter increment in fasting or non-fasting tHey above 10 j.mol/liter
is associated with a 60% (in men) to 80% (in women) greater risk
for coronary artery disease, and a 50% greater risk for cerebro-
vascular disease in both men and women. Three prospective
cohort studies [80—82] reported subsequent to this meta-analysis
confirmed that there is a graded association between non-fasting
tHey levels and incident myocardial infarction [80, 811 or stroke
[82], which persists after adjustment for the major established
arteriosclerotic risk factors. Finally a large, multicenter European
case control study recently confirmed that PML hyperhomocys-
teinemia confers a risk for prevalent CVD equal in magnitude to,
and independent of, fasting hyperhomocysteinemia [83].
Studies of ESRD populations
Conflicting findings, both across and within studies, have been
reported regarding the association between fasting tHey levels,
and the prevalence of clinical arteriosclerosis in ESRD patients
[49, 56—58, 62; Note added in proof, CI. Two of these investiga-
tions [49, 57] included only crude comparisons of mean tHey
levels between groups of ESRD patients with and without CVD.
A third study [56] adjusted inadequately for potential confound-
ing by the established CVD risk factors, and only observed a
"significant" increase in the tHey levels among men with CVD. In
a study of N = 75 maintenance dialysis patients [621, we found no
association between fasting tHey levels and prevalent CVD in
either crude (N = 22 with CVD, geometric mean tHey 20.4; N =
53 without CVD, geometric mean tHcy = 22.8; P = 0.297), or
multiple logistic regression analyses adjusted for age, sex, race,
total and HDL cholesterol levels, glucose intolerance/diabetes,
hypertension, smoking, and dialysis mode (odds ratio per mol/
liter increase in tHey = 0.99, 95% confidence interval = 0.91 to
1.07). A recent cross sectional report by Robinson and colleagues
[58j, in contrast, suggested that hyperhomocysteinemia (compar-
ing the upper to lower two tertiles of fasting tHey) conferred a
2.8-fold increased risk for prevalent arteriosclerotic outcomes in
maintenance dialysis patients, which persisted after adjustment
for age, sex, hypertension, hypercholesterolemia, and smoking.
Finally, in the largest cross-sectional study yet performed, we
found no association between non-fasting serum tHey levels and
non-fatal MI prevalence in the CANUSA [3] peritoneal dialysis
inception cohort. Baseline tHcy levels did not differ between 79
ESRD patients initiating peritoneal dialysis who had a clinical
history of myocardial infarction (MI) versus 366 similar patients
free of any history of cardiovascular disease (CVD), that is,
congestive heart failure, coronary heart disease, cerebrovascular
disease, or lower extremity arterial disease (tHey MI cases, 26.3
16.3 j.mol/L; ti-Icy no CVD, 27.6 23.3; P = 0.64). Crude and
mutivariable-adjusted (for age, sex, diabetes/glucose intolerance)
odds ratios (with 95% confidence intervals) comparing the highest
( 30.3 ,tmol/liter) to the lower three quartiles (< 30.3 j.tmol/
liter) of tHey, MI present versus MI/CVD absent, were 0.75 (0.41
to 1.35), and 0.78 (0.42 to 1.42), respectively (Note added in proof,
C). Intractable survivorship effects resulting from the excess yearly
mortality in dialysis-dependent ESRD [1, 3—5], and the failure to
establish whether or not arteriosclerotic outcomes antedated the
development of ESRD, renders any inference about tHcy-CVD
associations suggested by these published cross-sectional studies
hazardous [49, 56—58, 62; Note added in proof, C]. Such serious
methodologic limitations undermine the inherent validity of any
cross-sectional study evaluating putative risk factors for CVD in
ESRD populations. The potential relationship between hyperho-
mocysteinemia and arteriosclerotic outcomes in ESRD requires
more rigorous validation via prospective observational studies,
and ultimately, clinical tHey-lowering intervention trials.
The association between fasting tHey levels and CVD incidence
was examined in a preliminary, nested case-control study of 42
renal transplant recipients [53]. Post-hoc subgroup analyses indi-
cated that elevated fasting tHey levels predicted CVD incidence in
men, but not women. These findings are discordant with data from
much larger studies conducted in general populations, where sex
was not an effect modifier of the relationship between Hey and
CVD [79]. The inexplicable issue of effect modification by sex
notwithstanding, missing baseline covariate information (for ex-
ample, regarding the presence/absence of pre-existing CVD),
makes it impossible to discern whether the reported association
between tHey levels and incident CVD, even within the subgroup
of renal transplant recipient men, was free of important con-
founding factors [53]. Recently, we reported the results from a
prospective study of the relationship between fasting tHey levels
and CVD in 73 dialysis-dependent ESRD patients (Table 3) [15].
After a median follow-up of 17 months, 16 individuals experi-
enced incident non-fatal and/or fatal CVD events. Fasting hyper-
homocysteinemia [that is, comparing the upper (tHey  27
tmol/liter) to lower three quartiles (tHey < 27 mol/liter)]
conferred a significantly increased risk for incident CVD of
'—sevenfold for fatal events, and '—3.5-fold for pooled non-fatal
and fatal events, after adjustment for pre-existing CVD, the
established arteriosclerotic risk factors, ereatinine and albumin
levels, and dialysis adequacy. Further analyses revealed that
hyperhomocysteinemia conferred a similar risk for incident CVD
in women and men. Prospective studies of large ESRD cohorts
will be required to confirm the external validity of these findings.
HOMOCYSTEINE AND ARTERIOSCLEROSIS:
EXPERIMENTAL EVIDENCE
The pathologic mechanisms by which Hey promotes arterioscle-
rosis remain unclear. Experimental data support a range of
possibilities, including endothelial cell injury [84, 85], enhanced
low density lipoprotein oxidation [86], increased thromboxane-
mediated platelet aggregation [87], inhibition of cell surface
thrombomodulin expression and protein C activation [88], en-
hancement of lipoprotein (a)-fibrin binding [89], and promotion
of smooth muscle cell proliferation [90]. The in vivo relevance of
findings from such experimental studies, however, has been
seriously questioned [91, 92] due to their lack of specificity to Hey
versus other much more abundant plasma thiols, including cys-
teine, and the use of grossly supraphysiologic concentrations or
non-physiologic forms (that is, D-L as opposed to L-) of reduced
Hey. The data of Mansoor and colleagues [93] provide the
background appropriate for adequate understanding of the spe-
cific criticism regarding grossly supraphysiologic concentrations.
These investigators assessed concentrations of reduced Hey across
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the widest possible spectrum of tHcy concentrations. Their data
revealed that at tHcy concentrations of up to 100 mol/liter, levels
of reduced Hcy accounted for only 1% (1 molTh) of plasma
tHcy. When tHcy exceeded 100 jimol/liter, reduced Hcy began to
rise exponentially, likely due to saturation of plasma protein-
binding sites [93]. However, the highest reduced Hcy value they
documented was in a subject with homozygous homocystinuria
who had a tHey > 350 molIliter, but a reduced Hcy of < 100
tmol/liter [93]. When juxtaposed to the concentrations of reduced
Hcy used in experimental studies [84—88, 90], that is, 1000 to
10,000 mol/liter, the findings of Mansoor and colleagues [93]
illustrate the very dubious clinical relevance of these published
data. In contrast, physiologic models of mild, dietary-induced
hyperhomocysteinemia causing subclinical or frank atherothrom-
botic sequelae have recently been described in minipigs [94] and
cynomolgus monkeys [95]. Follow-up investigations employing
these models may elucidate the in vivo relevance of the putative
pathologic mechanisms cited above [84—90].
TREATMENT OF HYPERHOMOCYSTEINEMIA
Populations with normative renal function
The severe hyperhomocysteinemia found in homozygous cysta-
thionine beta synthase (CBS) deficiency has been treated with
methionine restriction and supraphysiologic doses of vitamin B-6,
vitamin B-12, folate, and betaine [24, 96]. Such treatment lowers
Hcy levels, and more importantly, reduces the incidence of
atherothrombotic events and mortality in these patients [24, 96].
Management of this severe form of hyperhomocysteinemia (that
is, tHcy levels of 100 to 400 tmol/liter) is the paradigm for
treatment of the more common mild to intermediate forms of
hyperhomocysteinemia. With the exception of methionine restric-
tion, all the major therapeutic approaches to lowering Hcy alluded
to earlier have been applied to populations with moderate hyper-
homocysteinemia.
Acknowledging the major limitation that few of the micronu-
trient trials for treatment of fasting hyperhomocysteinemia [97—
102], and none of the trials for treatment of PML hyperhomocys-
teinemia [103—1061 were placebo-controlled, some general
conclusions can be drawn from these published data:
(1.) Folic acid at 0.65 to 5.0 mg/day can effectively reduce
fasting Hey levels in moderately hyperhomocysteinemic and nor-
mohomocysteinemic persons with or without CVD who are free of
renal insufficiency, and are not vitamin B-12 deficient.
(2.) Vitamin B-12 (0.4 mg to 2.0 mg/day orally) can effectively
normalize fasting Hcy in vitamin B-12-—deficient persons who
respond only marginally to folic acid supplementation.(3.) Vitamin B-6 at doses up to 240 to 250 mg/day has no
lowering effect on fasting Hcy levels.
(4.) Vitamin B-6 at 20 to 250 mg/day appears to reduce the
absolute PML, or PML increase in Hcy levels, by —15 to 50% in
persons with or without CVD who have mild PML hyperhomo-
cysteinemia.
(5.) Even at doses of 250 mg/day vitamin B-6, combined with 5
mg/day folic acid, an effective fasting and/or PML Hcy-lowering
response may not be achieved in some individuals until after 6 to
12 weeks of treatment,
ESRD populations
With a single exception [106], all the published Hey-lowering
intervention studies conducted in ESRD patients were uncon-
trolled, open label investigations [54, 63, 64, 107—110]. Bearing
this important caveat in mind, the following conclusions can be
drawn from these studies:
(a) Folic acid-based B-vitamin regimens, including folic acid at
doses of 5 to 10 mg/day, appear to lower fasting tHcy levels by —30
to 50%.
(b) The addition of folic acid at 15 mg/day (vs. additional
placebo) to a baseline regimen including 1 mg/day of folic acid,
reduces fasting tHcy levels by -—-25 to 30%.
(c) Even when given a total dose of 16 mg/day of folic acid,
two-thirds of maintenance dialysis patients whose baseline fasting
or non-fasting tHcy levels are > 15 to 16 j.mol/1iter, will continue
to maintain tHey levels at or above this value.
(d) There are no data available on the independent effect of
B-12 on fasting tHcy levels.
(e) In accord with findings from general populations, B-6 at up
to 300 mg/day has no apparent effect on fasting tHcy levels. There
are no data on the independent effect of B-6 on PML tHcy levels.
(J) Neither serine at 3 to 4 g/day, nor betaine at 6 g/day appear
to have any effect on fasting tHcy levels.
(g) Oral N-acetylcysteine (NAC) at 1.2 g/day subacutely lowers
non-fasting pre-hemodialysis tHcy levels by —16%.
Finally, methionine restriction, as recently advocated [58, 1111,
would seem to be an inappropriate method to reduce tHcy levels
in dialysis-dependent ESRD patients given their tendency toward
inadequate dietary protein-energy intake, and the overall cata-
bolic stress they experience [112].
CONCLUSIONS AND FUTURE CONSIDERATIONS
There is an excess prevalence of B-vitamin refractory hyperho-
mocysteinemia in ESRD patients relative to age, sex, and race
matched, population-based controls free of renal disease. ESRD
hyperhomocysteinemia is due primarily to loss of renal Hcy
metabolism, which normally accounts for —70% of daily Hcy
elimination from plasma. The details of intrinsic renal Hcy
metabolism, however, are essentially unknown, and require elu-
cidation.
Due to intractable methodologic limitations, cross-sectional
studies of the association between Hcy levels and prevalent
arteriosclerotic disease in ESRD populations are invalid. Re-
cently, the first appropriately controlled, longitudinal evidence
was provided that hyperhomocysteinemia may contribute indepen-
dently to the excess incidence of fatal and non-fatal CVD outcomes
among maintenance dialysis patients. Confirmation of these prospec-
tive findings in large ESRD cohorts is urgently required.
Current treatment regimens for ESRD hyperhomocysteinemia,
which are based upon pharmacologic doses (that is, 5 to 15
mg/day) of folic acid, frequently result in suboptimal lowering of
tHcy levels. Other potential therapeutic approaches (such as oral
N-acetylcysteine) merit controlled investigation. Ultimately, pla-
cebo-controlled clinical trials of effective tHcy-lowering treat-
ments will be required to confirm the hypothesis that hyperhomo-
cysteinemia contributes independently to the excess incidence of
arteriosclerotic outcomes in ESRD.
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